India Begins Subjecting Liquid Medicines To Retail Price Caps
This article was originally published in PharmAsia News
All liquid medicines in India, including antibiotics and multivitamins, are to be subjected to price caps for the first time by the National Pharmaceutical Pricing Authority. Medicines in liquid form account for 15 percent of the retail market in India, and producers include all domestic drug makers. The drug-pricing authority has notified makers of the maximum retail prices set for 16 medicines that use any of 74 bulk drugs subject to price controls. The NPPA is preventing companies from avoiding the caps by covering all possible pack sizes up to 500ml. (Click here for more
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.